The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
Juan José SerranoTeresa Alonso GordoaJavier Lorca ÁlvaroJavier Molina-CerrilloArantzazu Barquín GarcíaOlga Martínez SáezJavier Burgos RevillaAlfredo CarratoSara Álvarez RodríguezPublished in: Therapeutic advances in urology (2021)
Some comorbidities may be strongly involved in patient outcomes when receiving API for mCRPC. In this sense, collaborative networking between specialists and caregivers treating prostate cancer (PC) patients should be recommended, focusing on MS features, cardiovascular and neurological disorders in order to anticipate medical and surgical complications.